지씨지놈
Financials
Valuation Metrics
지씨지놈's Market Cap is ₩1625B. Ranked #975 of 2,421 in KR market (top 40%), #483 of 1,640 on KOSDAQ (top 29%), #110 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 162.48B KRW | KR#975/2,421 Sec#110/231 |
| Revenue | 31.53B KRW | KR#2,015/2,421 Sec#139/231 |
| Net Income | 4.04B KRW | KR#1,278/2,421 Sec#90/231 |
| Total Assets | 84.63B KRW | KR#1,905/2,421 Sec#154/231 |
| Net Assets | 78.27B KRW | KR#1,605/2,421 Sec#131/231 |
| Value | ||
| P/E | 40.17x | KR#1,378/2,421 Sec#84/231 |
| P/B | 2.08x | KR#1,959/2,421 Sec#145/231 |
| P/S | 5.15x | KR#2,154/2,421 Sec#141/231 |
| EV/EBITDA | 103.08x | KR#1,491/2,421 Sec#98/231 |
| FCF Yield | 0.61% | KR#1,169/2,421 Sec#86/231 |
| Profitability | ||
| ROE | 5.17% | KR#1,080/2,421 Sec#74/231 |
| ROA | 4.78% | KR#766/2,421 Sec#61/231 |
| Op. Margin | 3.92% | KR#1,103/2,421 Sec#78/231 |
| Financial Health | ||
| Debt Ratio | 8.12% | KR#95/2,421 Sec#20/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 985.6M KRW | KR#1,149/2,421 Sec#87/231 |
| Cash | 35.12B KRW | KR#908/2,421 Sec#60/231 |
| Current Ratio | 18.59x | KR#32/2,421 Sec#13/231 |
| Net Debt/EBITDA | -28.42x | KR#14/2,421 Sec#1/231 |
| Performance | ||
| 1Y Return | -16.01% | KR#1,147/2,421 Sec#78/231 |
| 1M Return | 20.74% | KR#227/2,421 Sec#14/231 |
| From 52W High | -27.84% | KR#466/2,421 Sec#27/231 |
| 1Y MDD | -53.71% | KR#1,156/2,421 Sec#95/231 |
| Trading | ||
| Volume | 142,668 shares | KR#618/2,421 Sec#52/231 |
| Trading Value | 971.0M KRW | KR#726/2,421 Sec#73/231 |
| Foreign Own. | 3.11% | KR#1,252/2,421 Sec#115/231 |
| Per Share | ||
| EPS | 171 KRW | KR#1,327/2,421 Sec#87/231 |
| BPS | 3,310 KRW | KR#1,791/2,421 Sec#136/231 |
Company Info
GC Genome, established in 2013, is a specialized clinical genomics analysis company that listed on KOSDAQ under special provisions for technology growth companies in 2025. It offers customized molecular diagnostic solutions covering the entire life cycle in four business areas, including obstetrics examinations, and supplies genomics services to domestic tertiary general hospitals and clinics. The company is expanding its domestic and international business, including entering the United States and Thailand, strengthening service quality through technology advancement, and diversifying its product portfolio. GC Genome is headquartered in Yongin-si, Gyeonggi-do.